ORLANDO, Fla., June 28 /PRNewswire-FirstCall/ — Today
Novo Nordisk announced results of its STEPwise™ trial, which
identified a method of intensifying insulin treatment with
NovoLog® (insulin aspart [rDNA origin] injection). The study,
presented at the American Diabetes Association (ADA) 2010
Scientific Sessions, demonstrated a reduction of A1c levels in type
2 diabetes patients when a dose of NovoLog® was introduced at
meals, using two approaches that start with the largest meal of the
day, in addition to once-daily Levemir® (insulin detemir [rDNA
origin] injection) plus oral medications.
The 48-week open-label, randomized, multinational trial compared
two step-wise methods of gradually intensifying treatment with
NovoLog® in patients with type 2 diabetes taking once-daily
Levemir® plus oral medication:
- “SimpleSTEP” (fewer blood sugar measurements): Patients were
given their first routine daily dose of NovoLog® at their
largest meal and additional doses of NovoLog® were added in
sequence based on their blood sugar levels before the meal - “ExtraSTEP” (more frequent blood sugar measurements): Patients
were given their first routine daily dose of NovoLog® at the
meal with the largest increase in blood sugar before and after the
meal, and adjusted the dose amount based on the amount of rise in
blood sugar before and after the meal
After 12 weeks, patients in either arm who had an A1c of greater
than 7% received a second dose of NovoLog® at another meal. At
24 weeks, patients were held to the same A1c targets and given a
dose of NovoLog® at a third meal if A1c was still greater than
7%. After 48 weeks, investigators concluded that the step-wise
addition of NovoLog® to Levemir® plus oral medication,
as
‘/>”/>